SOFIVA GENOMICS Co (ROCO:6615) Stock Based Compensation: NT$0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6615 SOFIVA GENOMICS Co Ltd ROCO:6615
68 GF Score
Price NT$34.00
GF Value NT$31.65
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is SOFIVA GENOMICS Co Stock Based Compensation?

SOFIVA GENOMICS Co ROCO:6615 -1.02% 68 Stock Based Compensation is NT$0.0 Mil as of Mar. 2026. GuruFocus rates ROCO:6615 with a GF Score™ of 68/100 and a GF Value™ of NT$31.65 (Fairly Valued). The stock has 4 warning signs investors should review.

SOFIVA GENOMICS Co's Stock Based Compensation for the three months ended in Mar. 2026 was NT$0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was NT$0.0 Mil.

SOFIVA GENOMICS Co Stock Based Compensation Related Terms

SOFIVA GENOMICS Co Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for SOFIVA GENOMICS Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SOFIVA GENOMICS Co Stock Based Compensation Chart

SOFIVA GENOMICS Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.87 2.68 1.07 -0.73 -0.01

SOFIVA GENOMICS Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.00 0.00 0.00 0.00
ROCO:6615
68GF Score
SOFIVA GENOMICS Co Ltd ROCO:6615
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SOFIVA GENOMICS Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.0 Mil.

What does a Stock Based Compensation of NT$0.0 Mil mean?
SOFIVA GENOMICS Co (ROCO:6615) has a Stock Based Compensation of NT$0.0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for SOFIVA GENOMICS Co and its competitors.
Is SOFIVA GENOMICS Co's Stock Based Compensation too high?
SOFIVA GENOMICS Co's current Stock Based Compensation is NT$0.0 Mil. Overall, SOFIVA GENOMICS Co has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SOFIVA GENOMICS Co's Stock Based Compensation compare to TMO and DHR?
SOFIVA GENOMICS Co's Stock Based Compensation of NT$0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for SOFIVA GENOMICS Co and its competitors. SOFIVA GENOMICS Co's current Stock Based Compensation is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOFIVA GENOMICS Co stock overvalued right now?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co (ROCO:6615) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.65, compared to a current price of NT$34.00 — trading 7.4% above its estimated fair value. The current Stock Based Compensation is NT$0.0 Mil. SOFIVA GENOMICS Co's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For SOFIVA GENOMICS Co (ROCO:6615), the current Stock Based Compensation is NT$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SOFIVA GENOMICS Co (ROCO:6615) Overvalued in 2026?

Based on GuruFocus' analysis, SOFIVA GENOMICS Co stock appears to be overvalued. The current stock price of NT$34.00 is trading 7.4% above its estimated GF Value™ of NT$31.65. GuruFocus considers SOFIVA GENOMICS Co to be Fairly Valued.

Key valuation signals for ROCO:6615:

  • Stock Based Compensation: NT$0.0 Mil
  • GF Value™: NT$31.65 vs. price of NT$34.00 (7.4% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6615 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SOFIVA GENOMICS Co Business Description

Address No. 66-1, Section 1, Chongqing S. Road, 4th Floor, Zhongzheng District, Taipei, TWN, 10043
SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision Medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, prenatal, and neonatal genetic testing and medical testing, and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.
68GF Score

Get the complete analysis for ROCO:6615

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.00
Price
NT$31.65
GF Value